{"id":"W4283311019","doi":"10.1200/jco.22.00205","title":"Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"National Cancer Institute; AstraZeneca","keywords":"Medicine; Durvalumab; Metastatic Urothelial Carcinoma; Olaparib; Urothelial cancer; Oncology; Urothelial carcinoma; Internal medicine; Multicenter trial; Multicenter study; Urology; Gynecology; Randomized controlled trial; Bladder cancer; Cancer; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001325584,0.001025928,0.00162931,0.0002335354,0.0002809844,0.0007449885,0.0005731972,0.0009268961,0.003091811],"category_scores_gemma":[0.001260401,0.0004118854,0.000807808,0.0002980519,0.0006445991,0.0006595411,0.0002564748,0.001933443,0.0004376278],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005513605,"about_ca_system_score_gemma":0.0007356191,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005655934,"about_ca_topic_score_gemma":0.001563023,"domain_scores_codex":[0.9996887,0.0001774399,0.00001912245,0.00005564428,0.0000196619,0.0000394275],"domain_scores_gemma":[0.9994448,0.0001301487,0.0001500148,0.00003753676,0.00002606101,0.0002114154],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9343212,0.009672726,0.003431414,0.0006895177,0.0009592557,0.00009601636,0.0001271126,0.0006487505,0.009102394,0.0001486983,0.001597045,0.03920596],"study_design_scores_gemma":[0.9365861,0.05805285,0.00322551,0.00002499434,0.0003061978,0.00007875803,0.00001782242,0.000461481,0.0005568308,0.00006905609,0.0006116465,0.000008861022],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938641,0.00338478,0.0002207226,0.0004848648,0.0001571711,0.0007878071,0.0003891917,0.00005204751,0.0006593096],"genre_scores_gemma":[0.9942632,0.001787859,0.0007788491,0.0005577637,0.0002232154,0.0008846832,0.0005450989,0.000009717585,0.0009496667],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003091811,"threshold_uncertainty_score":0.01034313,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07433443946184327,"score_gpt":0.4213825141518132,"score_spread":0.34704807468997,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}